Nous voudrions effectuer une description ici mais le site que vous consultez ne nous en laisse pas la possibilité.En savoir plus Découvrez comment ouvrir Gmail et lire vos e-mails facilement sur ordinateur ou smartphone grâce à notre guide pratique pas à pas. 2 mars 2025 · Les 3 meilleures méthodes pour vous connecter à votre compte Gmail, accéder à votre boîte de réception et consulter vos emails (sur ordinateur, téléphone ou tablette, avec ou … 7 avr. 2025 · Vous débutez avec Gmail et vous ne savez pas comment accéder à votre compte ? Rien de plus simple ! Sur ordinateur comme sur mobile, vous n'avez besoin que de votre … Découvrez comment votre compte et vos e-mails sont chiffrés, et comment ils restent privés et sous votre contrôle dans Gmail, grâce au plus grand service de messagerie sécurisé au monde. Pour ouvrir Gmail, vous pouvez vous connecter à partir d'un ordinateur ou ajouter votre compte à l'application Gmail sur votre téléphone ou votre tablette. Une fois que vous êtes connecté, Search the world's information, including webpages, images, videos and more. Google has many special features to help you find exactly what you're looking for. Pour vous inscrire à Gmail, vous devez créer un compte Google. Le nom d'utilisateur et le mot de passe vous permettront de vous connecter à Gmail et à d'autres produits Google tels que … Restez à jour dans les e-mails que vous recevez et renforcez la sécurité de votre entreprise grâce à Gmail, un service sécurisé, intelligent et facile à utiliser. Par exemple, Gmail se synchronise avec Google Agenda et Google Maps pour que vous ayez toujours d'une longueur d'avance sur votre planning. De novo metastatic hormone-sensitive prostate cancer usually has a dismal prognosis, which has slightly improved in recent years thanks to the introduction of new hormonal agents and chemotherapy combined with androgen deprivation therapy from the Mar 12, 2024 · Overall survival (OS) in

metastatic hormone-sensitive prostate cancer (mHSPC) has improved in clinical trials over the last 20 years. 1, 2 It is unclear whether new treatments have translated to improvements in survival rates in clinical practice. We sought to quantify trends in OS among patients with newly diagnosed de novo (synchronous) mHSPC in 2 national registries in the United States Sep 9, 2024 · Prostate cancer treatments paradigms are in continuous evolution, especially in the metastatic setting. In this context, the Genito-Urinary Group of Italian Association of Radiotherapy and Clinical Oncology aimed to create a consensus on radiation therapy indication in de novo metastatic hormone-sensitive prostate cancer both on primary tumor and metastatic sites. Jul 16, 2025 · The treatment of metastatic hormone-sensitive prostate cancer has evolved rapidly, with the emergence of doublet and triplet therapies transforming outcomes. However, these advances bring new complexity and shift the clinical focus from intensification to personalization. Recent evidence, including major data presented at the 2025 ASCO Annual Meeting, on molecular profiling, biomarkers, and AI Explain the role of the PI3K/AKT pathway in prostate cancer biology. Explore collaborations between urologists, oncologists, radiologists, and other healthcare professionals in managing de novo mHSPC. Employ strategies to manage and mitigate common adverse events associated with AKT inhibitors and other therapies used in mHSPC. Dr. Karim Fizazi delved into why local treatment still matters for high-volume de novo metastatic hormone-sensitive prostate cancer. Dr. Fizazi highlighted that in patients with high-volume de novo metastatic hormone-sensitive prostate cancer (mHSPC), a key concern is managing severe local symptoms of metastatic disease. Newly presenting or de novo metastatic hormone-sensitive prostate cancer (mHSPC) accounts for 5% to 10% of all prostate cancer (PC) diagnoses, but it is responsible for nearly 50% of

PC-related deaths. 1 De novo mHSPC is characterized by an aggressive course with faster development of castration resistance and worse overall survival (OS) in Mar 21, 2023 · ADT–docetaxel–abiraterone–prednisone is recommended as first-line treatment for fit men with de novo metastatic hormone-sensitive prostate cancer (mHSPC), especially in those with multiple bone metastases (>3) or visceral metastases [I, B; European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) v1.1 score: 4 The median age of presentation of de novo metastatic prostate cancer based on registry data is 73–76 years [24 – 26], which is significantly higher than the age of the men recruited in all of the clinical trials. May 9, 2024 · This review assesses current evidence and emerging treatment strategies for improved survival among patients with metastatic hormone-sensitive prostate cancer and offers recommendations for clinical practice application.